Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07112183) titled 'Open Label Treprostinil Raynaud's Study' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Brigham and Women's Hospital
Condition:
Raynaud's Disease
Raynaud Phenomena
Raynauds
Intervention:
Drug: Oral treprostinil (UT-15C) sustained release tablets
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: August 1, 2025
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07112183...